Novel Potent Analgesic peptides derived from a endogenous protein to treat severe pain

CONECTUS ALSACE



15 Juillet 2015

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

A novel peptide-based pain-killer derived from an endogenous protein exhibits :

  • A higher level of analgesia than morphine
  • A peripheral indirect opioidergic activity with a long lasting effect

TECHNOLOGY

  • Peptide 4 shows at least 2 folds stronger analgesia than morphine on animal models at 4 hours (Von Frey Tests, intrathecal administration,
  • Peptide 4 displays a much better analgesic activity than morphine, at low doses (10 nm) in neuropathic model (n=10) with IP injection

APPLICATION

Treatment of moderate to severe pain, especially under chronic conditions.

INNOVATION ADVANTAGES

  • Peptide 4 exhibits greater analgesia than morphine on neuropathic models
  • Indirect opioidergic activity (Onset of 2-3 hours)
  • Long lasting effect
  • Endogenous ! (No immunogenicity)
  • Peripheral activity only (Tolerance +, side effect +)

DEVELOPMENT STATUS

  • MOA currently deeeply investigated
  • Program founded by Conectus in preparation, including: Early PK/TOX; In-Vivo efficacy on different pain Models; tolerance & side effects vs morphine; efficacy vs morphine.
Download the offer Download the offer

Newsletter